Q-omics provides the consensus-scored BAHD1 profile across patient tissues and cancer cell-line models. BAHD1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, BAHD1 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, BAHD1 RNA expression shows 20,409 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, HNSC, and UVM as cancer lineages where BAHD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BAHD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BAHD1 survival associations across molecular data types. BAHD1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BAHD1 RNA expression–survival associations across cancer types. High BAHD1 expression shows unfavorable associations in COAD and KICH, but favorable associations in MESO, KIRC, LUAD and UCEC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for BAHD1 RNA expression.
This table summarizes BAHD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BAHD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BAHD1 shows lower tumor expression in KIRC, COAD and LUAD and higher tumor expression in HNSC, LIHC and CHOL. The HNSC box plot shows higher BAHD1 RNA expression in tumor versus normal tissue (log2 FC = +0.718, t-test p < 0.001).
This table shows molecular features associated with BAHD1 in patient tissues and cancer cell lines. In patient samples, BAHD1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, BAHD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
